Clinical Research Directory
Browse clinical research sites, groups, and studies.
Ribociclib (LEE011) Rollover Study for Continued Access
Sponsor: Novartis Pharmaceuticals
Summary
This study is to allow continued use of ribociclib (LEE011) as single agent or in combination with other investigational treatments in patients benefitting from treatment in an eligible Novartis-sponsored ribociclib (LEE011) study that has reached its primary objective(s) or has been halted for other reasons.
Official title: An Open-label, Multi-center Rollover Protocol for Patients Who Have Participated in a Novartis-sponsored Ribociclib (LEE011) Study and Are Continuing to Benefit From Ribociclib as Single Agent or in Combination With Other Investigational Treatments
Key Details
Gender
All
Age Range
0 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
22
Start Date
2016-12-15
Completion Date
2027-02-01
Last Updated
2026-02-12
Healthy Volunteers
No
Interventions
LEE011
Single agent LEE011 or in combination with other treatments
Locations (13)
University Of Alabama At Birmingham
Birmingham, Alabama, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
The Regents of the Uni of Michigan
Ann Arbor, Michigan, United States
Broome Oncology
Johnson City, New York, United States
St Jude Childrens Research Hospital
Memphis, Tennessee, United States
Novartis Investigative Site
Lyon, France
Novartis Investigative Site
Villejuif, France
Novartis Investigative Site
Cologne, North Rhine-Westphalia, Germany
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Tainan, Taiwan
Novartis Investigative Site
Taipei, Taiwan